HC Wainwright reaffirmed their buy rating on shares of Medicenna Therapeutics (NASDAQ:MDNA – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price target on the stock. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at […]
Letko Brosseau & Associates Inc. increased its stake in shares of Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating) by 70.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 170,000 shares of the company’s stock after buying an additional 70,000 shares during […]
Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating)’s stock price dropped 1.8% during mid-day trading on Thursday . The stock traded as low as $0.74 and last traded at $0.74. Approximately 70,588 shares were traded during mid-day trading, a decline of 30% from the average daily volume of 100,742 shares. The stock had previously closed at […]
Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating) was down 1.8% on Thursday . The company traded as low as $0.74 and last traded at $0.74. Approximately 70,588 shares were traded during trading, a decline of 30% from the average daily volume of 100,742 shares. The stock had previously closed at $0.76. Analyst Ratings Changes Separately, […]